These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1562756)

  • 1. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy.
    Greene DA
    J Diabetes Complications; 1992; 6(1):35-8. PubMed ID: 1562756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aldose reductase inhibitors on the progression of nerve damage.
    Greene DA; Sima AA
    Diabet Med; 1993; 10 Suppl 2():31S-32S. PubMed ID: 8334837
    [No Abstract]   [Full Text] [Related]  

  • 3. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    J Diabetes Complications; 1992; 6(1):39-44. PubMed ID: 1562757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical application of aldose reductase inhibitors--prevention and therapy of diabetic complications].
    Hotta N; Sakamoto N
    Nihon Rinsho; 1987 Dec; 45(12):3010-27. PubMed ID: 3128677
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldose reductase inhibitors: the end of an era or the need for different trial designs?
    Pfeifer MA; Schumer MP; Gelber DA
    Diabetes; 1997 Sep; 46 Suppl 2():S82-9. PubMed ID: 9285505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can aldose reductase inhibition ameliorate diabetic neuropathy?
    González ER
    JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
    [No Abstract]   [Full Text] [Related]  

  • 13. Endoneurial microvessels in human diabetic neuropathy. Endothelial cell dysjunction and lack of treatment effect by aldose reductase inhibitor.
    Sima AA; Nathaniel V; Prashar A; Bril V; Greene DA
    Diabetes; 1991 Sep; 40(9):1090-9. PubMed ID: 1936616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural-functional interactions in the therapeutic response of diabetic neuropathy.
    Sima AA; Greene DA
    Diabet Med; 1993; 10 Suppl 2():33S-34S. PubMed ID: 8334838
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-function interactions in the therapeutic response of diabetic neuropathy.
    Sima AA
    J Diabetes Complications; 1992; 6(1):64-8. PubMed ID: 1562761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.
    Kamijo M; Cherian PV; Sima AA
    Diabetologia; 1993 Oct; 36(10):893-8. PubMed ID: 8243866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA; Lattimer SA
    Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
    Kador PF; Kinoshita JH; Sharpless NE
    J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.